Camrelizumab plus famitinib combo shows activity against advanced, metastatic RCC

Blockade of immune checkpoint and angiogenesis with camrelizumab and famitinib appears to be a promising strategy in the treatment of advanced or metastatic renal cell carcinoma (RCC), as shown in the results of a phase II basket study.

The study included 38 patients with advanced or metastatic RCC, among whom 13 (34.2 percent) were treatment-naïve and 25 (65.8 percent) had received prior treatment. All of them were given camrelizumab (200 mg intravenously every 3 weeks) and famitinib (20 mg orally once daily).

Over a median observation period of 16.5 months (range, 6.1–20.4), 23 patients achieved a confirmed objective response. The corresponding objective response rate (ORR) was 60.5 percent (95 percent confidence interval [CI], 43.4–76.0). Responses in 18 (78.3 percent) patients were still ongoing at data cutoff, and Kaplan–Meier estimated median duration of response had not been reached yet (range, 1.0 to 14.8 months).

Median progression-free survival (PFS) was 14.6 months (95 percent CI, 6.2–not reached).

In subgroup analysis, ORR was higher in the treatment-naïve group (84.6 percent, 95 percent CI, 54.6–98.1) than in the pretreated group (48.0 percent, 95 percent CI, 27.8–68.7). Median PFS had not been reached in the former and was 13.4 months (95 percent CI, 4.1–not reached) in the latter.

In terms of safety, the most common grade 3 or 4 treatment-related adverse events were proteinuria (18.4 percent), hypertension (18.4 percent), decreased neutrophil count (13.2 percent), palmar-plantar erythrodysesthesia syndrome (10.5 percent), and hypertriglyceridaemia (10.5 percent).

There were no treatment-related deaths documented, and no new safety signals were observed.